 CAMBRIDGE, Mass.--BUSINESS WIRE--Alnylam Pharmaceuticals, Inc. Nasdaq: ALNY, the leading RNAi therapeutics company, announced today new pre-clinical research results demonstrating continued RNAi therapeutics platform innovation and scientific leadership. The research was presented at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society OTS, held virtually from September 26 29, 2021. Among the presentations from Alnylam scientists, new pre-clinical data were presented iden 